Takatsuka Y, Shin E, Fukuda K, Mishima H, Tono T, Yagyuu T, Kobayashi K, Kikkawa N
Dept. of Surgery, Osaka National Hospital.
Gan To Kagaku Ryoho. 1995 Sep;22(11):1546-8.
Sixteen patients with advanced breast cancer were treated with neoadjuvant intraarterial chemotherapy with high dose epirubicin. The following results were obtained: 1) Excellent down-staging effects were confirmed. Response rate of the primary tumor was 81.3%. 2) Leukopenia was the dose-limiting factor, and 81.3% of patients had WHO grade 2 or more leucopenia. However, the regimen was completed with supportive therapies. 3) At a median follow-up of 17 months, improved survival rates were noted. The present study showed the efficacy of neoadjuvant intraarterial chemotherapy with high dose epirubicin in the treatment of locally advanced breast cancer.
16例晚期乳腺癌患者接受了高剂量表柔比星新辅助动脉内化疗。获得了以下结果：1）证实了极佳的降期效果。原发肿瘤的缓解率为81.3%。2）白细胞减少是剂量限制因素，81.3%的患者出现世界卫生组织2级或更高级别的白细胞减少。然而，通过支持性治疗完成了该方案。3）在中位随访17个月时，观察到生存率有所提高。本研究显示了高剂量表柔比星新辅助动脉内化疗在治疗局部晚期乳腺癌中的疗效。
